Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Neurogene (NGNE) Research & Development (2018 - 2025)

Neurogene's Research & Development history spans 6 years, with the latest figure at $20.6 million for Q4 2025.

  • For Q4 2025, Research & Development rose 34.48% year-over-year to $20.6 million; the TTM value through Dec 2025 reached $75.0 million, up 23.13%, while the annual FY2025 figure was $75.0 million, 23.14% up from the prior year.
  • Research & Development reached $20.6 million in Q4 2025 per NGNE's latest filing, up from $17.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.6 million in Q4 2025 to a low of $10.3 million in Q1 2023.
  • Average Research & Development over 3 years is $15.0 million, with a median of $15.5 million recorded in 2024.
  • Peak YoY movement for Research & Development: soared 52.54% in 2024, then increased 5.87% in 2025.
  • A 3-year view of Research & Development shows it stood at $12.2 million in 2023, then rose by 25.96% to $15.3 million in 2024, then soared by 34.48% to $20.6 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Research & Development are $20.6 million (Q4 2025), $17.2 million (Q3 2025), and $19.4 million (Q2 2025).